Epoetin to improve outcomes in severe trauma ICU patients
Part of Brain & nervous system, Injuries & trauma clinical trials.
This trial tests epoetin alfa (a blood-building medicine) to help reduce death and severe disability in critically ill trauma patients in the ICU. You may be considered if your ICU team expects a longer stay and the timing after injury is early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old
- You were admitted to the ICU from a traumatic injury within 24 hours
- You are on a breathing machine through a tube (invasive mechanical ventilation)
- The ICU team expects you to stay in the ICU for at least 48 hours
- Your hemoglobin level is not above the usual “normal” range used at your hospital
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether giving fibrinogen early can improve outcomes for adults with serious trauma who are actively bleeding. The goal is to help blood clotting work better sooner and potentially reduce complications from uncontrolled bleeding.
This trial looks at two medicines (PCC and recombinant activated Factor VIIa) that help blood clot, to see which works better for trauma patients who need a lot of blood transfusions. If you have a severe injury and need many blood transfusions quickly, this study may help identify the best treatment.
This trial compares giving whole blood versus standard care in adults with severe trauma and dangerous blood loss (hemorrhagic shock). The goal is to see if whole blood helps stabilize patients faster and improves outcomes after major bleeding.
This trial tests whether a combination of epoetin alfa (a medicine that boosts red blood cell production) and iron derisomaltose (an iron supplement) can safely treat anemia in people with sepsis or septic shock. It may help improve your energy and recovery.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests whether giving platelet transfusions to critically ill patients with very low platelet counts helps prevent bleeding. If you are in the ICU with low platelets and need life support, this study may be relevant to you.
Hear when a new Trauma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.